Maravai LifeSciences (MRVI) Stock Forecast & Price Target

$9.16

+0.65 (+7.64%)

(As of 07/26/2024 ET)

Maravai LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Maravai LifeSciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 3 have given a hold rating, and 7 have given a buy rating for MRVI.

Consensus Price Target

$11.44
24.94% Upside

High Forecast	$17.00
Average Forecast	$11.44
Low Forecast	$7.00

According to the 10 analysts' twelve-month price targets for Maravai LifeSciences, the average price target is $11.44. The highest price target for MRVI is $17.00, while the lowest price target for MRVI is $7.00. The average price target represents a forecasted upside of 24.94% from the current price of $9.16.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.44	$11.44	$11.56	$19.80
Forecasted Upside	24.94% Upside	53.18% Upside	49.88% Upside	41.82% Upside

Get Maravai LifeSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.

Ad Stansberry Research

Get out of cash before the Fed's next meeting

"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."

Click here now to watch this exclusive interview

MRVI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRVI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Maravai LifeSciences Stock vs. The Competition

Type	Maravai LifeSciences	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	24.94% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
7/9/2024	The Goldman Sachs Group 2 of 5 stars	Lower Target	Neutral ➝ Neutral	$8.00 ➝ $7.00	-4.63%
5/9/2024	Robert W. Baird 2 of 5 stars	Boost Target	Outperform ➝ Outperform	$8.00 ➝ $10.00	+12.74%
4/10/2024	Craig Hallum 4 of 5 stars	Initiated Coverage	Buy	$15.00	+76.26%
2/23/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$12.00 ➝ $14.00	+72.20%
2/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$11.00 ➝ $10.00	+95.69%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$10.00 ➝ $8.00	+55.34%
Get the Latest News and Ratings for MRVI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.
11/9/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$12.00 ➝ $11.00	+132.07%
8/8/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$23.00 ➝ $17.00	+52.60%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$14.00 ➝ $11.00	-0.18%
8/8/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Sector Weight
5/23/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Downgrade
1/5/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$20.00 ➝ $16.00	+14.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:43 AM ET.

MRVI Forecast - Frequently Asked Questions

What is Maravai LifeSciences' forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Maravai LifeSciences is $11.44, with a high forecast of $17.00 and a low forecast of $7.00.
Should I buy or sell Maravai LifeSciences stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRVI shares.
Does Maravai LifeSciences's stock price have much upside?: According to analysts, Maravai LifeSciences's stock has a predicted upside of 47.12% based on their 12-month stock forecasts.
What analysts cover Maravai LifeSciences?: Maravai LifeSciences has been rated by research analysts at Robert W. Baird, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Maravai LifeSciences more than its competitors?: Analysts like Maravai LifeSciences less than other "medical" companies. The consensus rating score for Maravai LifeSciences is 2.70 while the average consensus rating score for "medical" companies is 2.72. Learn more on how MRVI compares to other companies.